Nicolas Soldermann

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

V. Koneti Rao, Sharon Webster, Virgil A. S. H. Dalm et al. · Blood · 2017 · 276 citations · Full text

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric J. Zécri et al. · ACS Medicinal Chemistry Letters · 2017 · 111 citations · Full text

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 104 citations · Full text

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer et al. · ACS Medicinal Chemistry Letters · 2016 · 65 citations · Full text

Origins of Boat or Chair Preferences in the Ireland−Claisen Rearrangements of Cyclohexenyl Esters:  A Theoretical Study

Mahmood M. Khaledy, M. Yashar S. Kalani, Kelli S. Khuong et al. · The Journal of Organic Chemistry · 2002 · 45 citations